Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 68

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 68
---
if any, will be derived from sales of product candidates that we do not expect to be commercially available for the next couple of years,
if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional
financing may not be available to us on acceptable terms, or at all. For example, the trading prices for our and other biopharmaceutical
companies’ stock have been highly volatile as a result of current macroeconomic conditions and market volatility. As a result,
we may face difficulties raising capital through sales of our common stock on acceptable terms, if at all. If we are unsuccessful in
securing sufficient financing, we may need to delay, reduce, or eliminate our research and development programs, which could adversely
affect our business prospects, or cease operations. For additional information, see Note 1 to our unaudited condensed consolidated financial
statements included elsewhere in this Quarterly Report.

Contractual
Obligations

Operating
lease liabilities represent our commitment for future rent made under a non-cancelable lease for our offices in San Diego, CA. As of
September 30, 2025, the total remaining payments under this operating lease obligation were approximately $9,000. The lease expired on
October 31, 2025. For additional details regarding our lease, see Note 8 to our unaudited condensed consolidated financial statements
included in this Quarterly Report.

We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under the SEC
rules.

8

Critical
Accounting Policies

This
discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial
statements requires us to make estimates that affect the reported amounts of our assets, liabilities and expenses. Significant accounting
policies employed, including the use of estimates, are presented in the notes to our annual financial statements included in our 2024
Annual Report on Form 10-K. We periodically evaluate our estimates, which are based on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances. Critical accounting policies are those that are most important to the portrayal
of our financial condition and results of operations and require our subjective or complex judgments, resulting in the need to make estimates
about the effect of matters that